Global Migraine Drugs Market: Snapshot

The global market for migraine drugs has been growing at a healthy pace and is likely to exhibit a promising growth rate in the coming few years. The rising cases of migraine and the rapid development of the healthcare infrastructure in emerging economies are estimated to support the overall growth of the global migraine drugs market in the next few years.

As per the market research study by Transparency Market Research, in 2016, the global market for migraine drugs stood at US$2.72 bn and is projected to reach US$3.72 bn by 2025. The market is expected to register a healthy 3.50% CAGR between 2017 and 2025.

Development of New Drugs to Enhance Growth of Migraine Drugs Market

In the last few years, the unhealthy food habits and hectic lifestyle of consumers resulting in migraine and other disorders are projected to encourage the development of the global migraine drugs market in the coming few years. The rising population and the increasing awareness among consumers concerning migraine are further predicted to ensure the overall growth of the market in the coming few years. In addition to this, the development of new drugs is anticipated to accelerate the market development in the coming years.

On the contrary, the high consumption of migraine drugs resulting in several side effects are anticipated to curtail the growth of the migraine drugs market in the coming few years. Moreover, the lack of awareness among people related to migraine and its drugs, particularly in under developed regions is estimated to curb the overall growth of the market in the next few years. Nevertheless, the rising number of initiatives that are being taken by private as well as public healthcare organization and market players to create consumer awareness and enhance the distribution network are predicted to accelerate the development of the market in the near future.


North America and Europe to Witness High Growth in Migraine Drugs Market

Presently, North America is expected to account for a huge share of the global migraine drugs market over the next few years. This region is anticipated to register a healthy 3.40% CAGR between 2017 and 2025, thanks to the rising healthcare expenditure. In addition to this, the easy availability of specialty migraine drugs and the increasing cases of migraine are projected to support the development of this region in the coming years. Furthermore, Europe is estimated to attain the second position in the coming years. The rising awareness among people concerning the availability of drugs and therapeutics for migraine is projected to ensure the market growth in the near future. Asia Pacific, on the other hand, is likely to observe a substantial growth in the near future with the growing demand and contribution from China and India.

The competition among the key players in the migraine drugs market is expected to get intense over the coming few years. The presence of a strong drugs pipeline and the development of new products are anticipated to ensure the growth of the overall market in the next few years. In addition, the growing research activities, which is predicted to create several opportunities is likely to support market growth in the coming few years. The key players in the migraine drugs market across the globe are Novartis AG, Allergan Plc., Alder BioPharmaceuticals Inc., Avanir Pharmaceuticals, Inc., Eisai Co., Ltd., Janssen Pharmaceutical Company, Eli Lilly & Co., Zosano Pharma Corporation, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Endo Pharmaceuticals Inc., AstraZeneca Plc., Merck & Co., Inc., and Pfizer, Inc.

Global Migraine Drugs Market: Scope and Methodology

This report on the global migraine drugs market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment and sub-segment for the period from 2017 to 2025, considering the macro and micro environmental factors. Growth rates for each segment within the global migraine drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global migraine drugs market.

Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year and 2015 as historic year. Market size estimations involved in-depth study of product features of different types of treatments & drug class and various pipeline products. Additionally, market related factors such as preference for self-medication, regional availability of specialty drugs, patent expiration of migraine drugs & availability of generic drugs, projected launch of new drugs etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Migraine Drugs Market: Segmentation

Migraine is type of headache, estimated to affect 12 to 14.7% of population across the globe. According to international as well regional guidelines it is categorized by frequency and nature of attack into episodic migraine and chronic migraine. Abortive and prophylactic are the two treatments offered for migraine relief. Abortive treatment which is given to abort acute attack of migraine include medication such as triptans, ergot alkoids and others. While prophylactic treatment is recommended to patients with chronic migraine to prevent migraine attacks using medications such as botulinum toxin, topiramate and other drugs.

Based on treatment, the global migraine drugs market has been segmented into abortive and prophylactic. These treatments segments are further classified based on the drug class such as abortive treatment is classified into triptans, ergot alkoids, and others while prophylactic treatment is segmented into botulinum toxin, topiramate and others. Abortive treatment segment is projected to hold dominant share of global migraine drugs market while prophylactic treatment segment is likely to register steady growth during the forecast period from 2017 to 2025.

Based on route of administration, the global migraine drugs market is segmented into oral, injectable and others. Others segment of route of administration include nasal sprays, transdermal patches, etc. Low cost and vast availability of orally administrable drugs is projected to contribute for dominating share of oral segment of route of administration.

Based on the distribution channel, the global migraine drugs market is segmented into retail pharmacies, hospital pharmacies and others. Ever increasing number of retail pharmacies, self-medication with widely available OTC migraine abortive drugs is attributed for the significant share of the segment in the global market.

Migraine Drugs Market: Geographical and Competitive Dynamics

Geographically, the global migraine drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region.

The report also profiles major players in the migraine drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include AstraZeneca Plc., Allergan Plc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc., Eli Lilly & Co. Novartis AG, Merck & Co., Inc., Valeant Pharmaceutical International, Inc., Janssen Pharmaceutical Company (Johnson & Johnson), Endo Pharmaceuticals Inc., Zosano Pharma Corporation, Alder BioPharmaceuticals Inc., and others.

The global migraine drugs market has been segmented as below:

Global Migraine Drugs Market, by Treatment

  • Abortive
    • Triptans
    • Ergot Alkaloids
    • Others
  • Prophylactic
    • Botulinum Toxin
    • Topiramate
    • Others

Global Migraine Drugs Market, by Route of Administration

  • Oral
  • Injectable
  • Others (Nasal Spray, Transdermal Patch, etc.)

Global Migraine Drugs Market, by Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Others (Online Pharmacies, Drug Stores, etc.)

Global Migraine Drugs Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Israel
    • Rest of Middle East and Africa